Welcome to our dedicated page for Coherus Oncology SEC filings (Ticker: CHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Coherus Oncology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Coherus Oncology's regulatory disclosures and financial reporting.
Coherus Oncology, Inc. director Jill O'Donnell-Tormey reported equity awards in the form of common stock and stock options. She received 30,000 shares of Common Stock as restricted stock units, at no purchase price, with 30,000 shares held directly after this grant.
She was also granted stock options for 60,000 shares of Common Stock with an exercise price of $1.45 per share, expiring on June 5, 2036. According to the footnotes, the 30,000 RSUs vest in full on the one year anniversary of June 3, 2026, and the 60,000 options vest and become exercisable in full on June 3, 2027, in each case subject to her continued service with the company.
Coherus Oncology, Inc. director Mats Wahlstrom reported equity awards consisting of common stock and stock options as compensation. He received 30,000 shares of Common Stock that constitute restricted stock units, each converting into one share upon vesting. These RSUs vest 100% on the one-year anniversary of June 3, 2026, contingent on his continued service. He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, vesting in full on June 3, 2027, also subject to continued service, and expiring on June 5, 2036. Following these awards, Wahlstrom holds 30,000 shares of Common Stock directly and 60,000 stock options.
Coherus Oncology director Charles W. Newton reported equity compensation grants. He received 30,000 shares of Common Stock in the form of restricted stock units, with one share delivered for each unit upon vesting. The RSUs vest 100% on the one year anniversary of June 3, 2026, contingent on his continued service.
He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, expiring on June 5, 2036. These options vest and become exercisable in full on June 3, 2027, also subject to his continued service. After these awards, he holds 30,000 shares of Common Stock and 60,000 options directly.
Coherus Oncology Chief Financial Officer granted repriced options
Coherus Oncology, Inc. reported that its Chief Financial Officer, Bryan J. McMichael, received several grants of stock options on May 29, 2026, each with an exercise price of $1.59 per share and expirations on May 29, 2036. These options cover multiple blocks, including grants for 100,000, 30,000, 25,000, 25,000, 25,000, and 15,000 shares of common stock as compensation.
On the same date, the company recorded dispositions of earlier stock options back to the issuer, in matching share amounts but with higher exercise prices ranging from $5.44 to $14.76 per share, reflecting a stockholder-approved option repricing for options previously priced at or above $5. No open‑market purchases or sales of common stock were reported in this filing.
Coherus Oncology, Inc. reported that President & CEO Dennis M. Lanfear received multiple stock option grants covering a total of 3,205,000 shares of common stock at an exercise price of $1.59 per share. These new options replace an equal number of older options with exercise prices ranging from $5.44 to $18.33, which were disposed of back to the company.
Stockholders approved this option repricing on May 29, 2026, and the repricing is conditioned on Lanfear remaining in service through May 29, 2027. One block of options vests in 1/48th monthly installments measured from January 5, 2023, while another block is fully vested and exercisable, aligning his compensation structure more closely with the current share price.
Coherus Oncology, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected Class III directors Dennis M. Lanfear and Mats L. Wahlström to serve until the 2029 annual meeting. At the record date on April 16, 2026 there were 154,217,609 common shares outstanding, each entitled to one vote.
Stockholders ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approved a non-binding Say-on-Pay resolution for executive compensation. They also approved a reduction in the exercise price of certain outstanding stock options and an increase in the shares reserved under the Amended and Restated 2014 Equity Incentive Award Plan, both equity-related items that can affect future dilution and employee incentives.
Coherus Oncology, Inc. reporting person Timothy G. Youngquist 2020 Irrevocable Trust amended its Schedule 13G to state it beneficially owns 12,750,800 shares of common stock, representing 8.3% of the class based on April 16, 2026 outstanding shares. The filing notes inclusion of 460,000 shares issuable under call options exercisable within 60 days for purposes of Rule 13d-3. The amendment (No. 2) corrects information in a prior amendment and is signed by the trust's manager on May 15, 2026.
Coherus Oncology reported first-quarter 2026 net revenue of $12.3 million, up from $7.6 million a year earlier, driven mainly by LOQTORZI sales of $11.8 million. Gross margin from continuing operations improved to 69%, reflecting higher oncology volume.
The company still posted a net loss of $38.3 million versus $56.6 million in 2025, with continuing operations accounting for a $36.9 million loss. Coherus strengthened liquidity through a February 2026 equity offering, raising $53.6 million net and ending the quarter with $167.0 million in cash, cash equivalents and marketable securities.
Coherus Oncology reported first quarter 2026 results showing early progress in its oncology transition. Net revenue from continuing operations was $12.3 million, up from $7.6 million a year earlier, driven by LOQTORZI net revenue of $11.8 million in the quarter.
GAAP net loss from continuing operations narrowed to $36.9 million, or $(0.27) per share, versus $47.4 million, or $(0.41) per share, with lower R&D and SG&A reflecting the 2025 exit from the biosimilar business. Non-GAAP net loss from continuing operations was $33.9 million, or $(0.25) per share. Cash, cash equivalents and marketable securities totaled $167.0 million as of March 31, 2026, while the company highlighted clinical progress for tagmokitug and casdozokitug alongside its LOQTORZI commercial ramp.
Coherus Oncology, Inc. Schedule 13G/A amendment shows the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 12,790,800 shares of common stock, representing 8.267% of the class. The filing states this percentage is based on 154,217,609 shares outstanding as of April 16, 2026 and includes 500,000 shares underlying call options deemed outstanding for purposes of Rule 13d-3.